Medpace Holdings (FRA:01P) ROCE % : 53.08% (As of Mar. 2024)

View and export this data going back to 2016. Start your Free Trial

What is Medpace Holdings ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Medpace Holdings's annualized ROCE % for the quarter that ended in Mar. 2024 was 53.08%.

Medpace Holdings ROCE % Historical Data

The historical data trend for Medpace Holdings's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Medpace Holdings ROCE % Chart

Medpace Holdings Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

ROCE %

Get a 7-Day Free Trial

17.03

18.29

20.01

35.22

51.94

Medpace Holdings Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
ROCE %	Get a 7-Day Free Trial															64.53	57.41	56.27	51.75	53.08

Medpace Holdings ROCE % Calculation

Medpace Holdings's annualized ROCE % for the fiscal year that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	308.869	/	( ( (1276.755 - 758.476)	+	(1519.311 - 848.345) )	/ 2 )
	=	308.869	/	( (518.279	+	670.966)	/ 2 )
	=	308.869	/	594.6225
	=	51.94 %

Medpace Holdings's ROCE % of for the quarter that ended in Mar. 2024 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Mar. 2024 )		(Q: Dec. 2023 )		(Q: Mar. 2024 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Mar. 2024 )		(Q: Dec. 2023 )		(Q: Mar. 2024 )
	=	382.972	/	( ( (1519.311 - 848.345)	+	(1652.126 - 880.113) )	/ 2 )
	=	382.972	/	( ( 670.966	+	772.013 )	/ 2 )
	=	382.972	/	721.4895
	=	53.08 %

(1) Note: The EBIT data used here is four times the quarterly (Mar. 2024) EBIT data.

Medpace Holdings (FRA:01P) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Medpace Holdings ROCE % Related Terms

Thank you for viewing the detailed overview of Medpace Holdings's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

Medpace Holdings (FRA:01P) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Medpace Holdings Inc (FRA:01P) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

MEDP:USA MEDP:Mexico 01P:Germany

Address

5375 Medpace Way, Cincinnati, OH, USA, 45227

Website

https://www.medpace.com

Medpace is a late-stage contract research organization, or CRO, that provides full-service drug development and clinical trial services to small and midsized biotechnology, pharmaceutical, and medical device firms. Medpace also offers ancillary services such as bio-analytical laboratory services and imaging capabilities. The company was founded over 30 years ago, and it has over 5,400 employees across 40 countries. Medpace is headquartered in Cincinnati, Ohio, and its operations are principally based in the U.S., but it also operates in Europe, Asia, South America, Africa, and Australia. Cinven, a global private equity firm, acquired Medpace for $915 million in February 2014, and it exited Medpace in August 2018.

Medpace Holdings (FRA:01P) Headlines

No Headlines